ES2190241T3 - Compuestos farmaceuticos de liberacion rapida de substancias medicamentosas. - Google Patents

Compuestos farmaceuticos de liberacion rapida de substancias medicamentosas.

Info

Publication number
ES2190241T3
ES2190241T3 ES99941418T ES99941418T ES2190241T3 ES 2190241 T3 ES2190241 T3 ES 2190241T3 ES 99941418 T ES99941418 T ES 99941418T ES 99941418 T ES99941418 T ES 99941418T ES 2190241 T3 ES2190241 T3 ES 2190241T3
Authority
ES
Spain
Prior art keywords
composition
powder
active substance
sieve
therapeutically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99941418T
Other languages
English (en)
Inventor
Poul Bertelsen
Nils Gjerl V Hansen
Hermann Ruckendorfer
Shigeru Itai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharma AS
Original Assignee
Nycomed Danmark AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Danmark AS filed Critical Nycomed Danmark AS
Application granted granted Critical
Publication of ES2190241T3 publication Critical patent/ES2190241T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuesto farmacéutico de liberación rápida para administración oral, que comprende una substancia terapéutica y/o profilácticamente activa, cuya substancia activa queda definida por una de las características i) o ii): i) la substancia activa tiene una solubilidad máxima de 0, 1 % peso/volumen en ácido clorhídrico 0, 1 N a temperatura ambiente; ii) la substancia activa tiene un valor pKa máximo de 5, 5, y en el que el compuesto farmacéutico de liberación rápida tiene además una de las características iii) o iv): iv) el compuesto farmacéutico de liberación rápida se basa en un material en polvo que comprende la substancia terapéutica y/o profilácticamente activa y que tiene un tamaño de partículas que, cuando el material en polvo es sometido a análisis de cribado, como mínimo, 90 % peso/peso de las partículas atraviesan una criba de 180 µm, estableciendo contacto el material en polvo con un medio acuoso para formar un compuesto en partículas, que tiene un tamaño de partículas tal que, cuando el compuesto en partículas es sometido a análisis de cribado, entonces un mínimo de 50 % peso/peso de las partículas atraviesan una criba de 180 µm; iv) el compuesto farmacéutico de liberación rápida adopta la forma de compuesto en partículas o se basa en un compuesto en partículas, que es obtenido por contacto de un material en polvo que comprende la substancia terapéutica y/o profilácticamente activa con un medio acuoso de manera tal que el tamaño medio de partículas del compuesto es como máximo 100 % superior al tamaño medio de partículas del material en polvo antes de contacto con el medio acuoso, y en el que el compuesto farmacéutico de liberación rápida es tal que la substancia activa recibe el contacto de una substancia alcalina, y en el que el compuesto farmacéutico de liberación rápida, una vez comprobada de acuerdo con el método de disolución I que se ha definido utilizando ácido clorhídrico 0, 07 N como medio de disolución, libera un mínimo de 50 % peso/peso de la substancia activa dentro de los primeros 20 minutos de la prueba.
ES99941418T 1998-09-10 1999-09-10 Compuestos farmaceuticos de liberacion rapida de substancias medicamentosas. Expired - Lifetime ES2190241T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA199801143 1998-09-10

Publications (1)

Publication Number Publication Date
ES2190241T3 true ES2190241T3 (es) 2003-07-16

Family

ID=8101500

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99941418T Expired - Lifetime ES2190241T3 (es) 1998-09-10 1999-09-10 Compuestos farmaceuticos de liberacion rapida de substancias medicamentosas.

Country Status (13)

Country Link
US (1) US6713089B1 (es)
EP (1) EP1109534B1 (es)
JP (2) JP5026635B2 (es)
AT (1) ATE232382T1 (es)
AU (1) AU5504599A (es)
CA (1) CA2343148C (es)
DE (1) DE69905380T2 (es)
DK (1) DK1109534T3 (es)
EA (1) EA004032B1 (es)
ES (1) ES2190241T3 (es)
PT (1) PT1109534E (es)
TR (1) TR200100708T2 (es)
WO (1) WO2000015195A1 (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US8231899B2 (en) * 1998-09-10 2012-07-31 Nycomed Danmark Aps Quick release pharmaceutical compositions of drug substances
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
EP1250921A1 (en) * 2001-04-21 2002-10-23 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Fast disintegrating meloxicam tablet
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US20030161875A1 (en) * 2002-02-27 2003-08-28 Deepak Murpani Fast dissolving tablets of cyclooxygenase-2 enzyme inhibitors
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US20040109889A1 (en) * 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
WO2005004915A2 (en) * 2003-07-09 2005-01-20 Boehringer Ingelheim International Gmbh Compositions comprising meloxicam
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
US20050220877A1 (en) * 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1916994B1 (en) * 2004-06-29 2013-12-11 Takeda Pharma A/S Manufacturing of quick release pharmaceutical composition of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention
JP5490347B2 (ja) * 2005-05-27 2014-05-14 エスエス製薬株式会社 経口投与用製剤
JO3352B1 (ar) 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
MX2008000967A (es) 2005-07-20 2008-03-26 Panacea Biotec Ltd Nueva composicion farmaceutica de forma de dosis de liberacion modificada que comprende inhibidor de enzima ciclooxigenasa.
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
US20070154542A1 (en) * 2005-12-30 2007-07-05 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
EP2019586A4 (en) * 2006-05-03 2009-09-02 Proethic Pharmaceuticals Inc MEDICATION OF ACUTE PAIN BASED ON FAST DICLOFENAC OPIOID COMBINATIONS
WO2008008120A1 (en) * 2006-07-14 2008-01-17 Fmc Corporation Solid form
WO2008062449A2 (en) * 2006-09-18 2008-05-29 Glenmark Pharmaceuticals Limited A novel pharmaceutical soft gel composition containing dexibuprofen and paracetamol
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
HUE029236T2 (en) * 2007-06-13 2017-02-28 Incyte Holdings Corp (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
EP2471516A3 (en) 2007-09-14 2012-12-26 Wockhardt Limited Rhein or diacerein compositions
WO2009089134A1 (en) 2008-01-04 2009-07-16 Src, Inc. Methods for measuring a patint response upon administration of a drug and compositions thereof
JP5757864B2 (ja) 2008-05-20 2015-08-05 ニューロジェシックス， インコーポレイテッド 水溶性アセトアミノフェン類似体
KR101677126B1 (ko) 2008-05-20 2016-11-22 노이로제스엑스, 인코포레이티드 탄산염 프로드러그 및 그것의 사용 방법
EA201100313A1 (ru) 2008-09-09 2011-10-31 Астразенека Аб Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
EP2432472B1 (en) 2009-05-22 2019-10-02 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
CA2764963C (en) 2009-06-25 2016-11-01 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
US20110008432A1 (en) * 2009-06-25 2011-01-13 Pozen Inc. Method for Treating a Patient in Need of Aspirin Therapy
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
MX2012004177A (es) 2009-10-12 2012-05-08 Boehringer Ingelheim Vetmed Recipiente para composiciones que comprenden meloxicam.
US9149480B2 (en) 2010-03-03 2015-10-06 Boehringer Ingeleheim Vetmedica GmbH Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
AR084691A1 (es) 2010-05-21 2013-06-05 Incyte Corp Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
EP2394641A1 (en) 2010-05-30 2011-12-14 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of lornoxicam
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012146314A1 (en) 2011-04-29 2012-11-01 Refarmed Chemicals Sa Thin gelatin capsules for rapid drug release in the mouth
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
JP2012012411A (ja) * 2011-10-03 2012-01-19 Ssp Co Ltd 経口投与用製剤
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
US9993422B2 (en) 2012-04-18 2018-06-12 SpecGx LLC Immediate release, abuse deterrent pharmaceutical compositions
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
TWI761825B (zh) 2012-11-15 2022-04-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
MX384910B (es) 2013-03-06 2025-03-14 Incyte Holdings Corp Procesos e intermedios para hacer un inhibidor de jak.
PL2968182T3 (pl) 2013-03-15 2018-10-31 SpecGx, LLC Zniechęcająca do nadużywania stała postać dawkowania dla natychmiastowego uwalniania z funkcjonalnym rowkiem
JP2013216701A (ja) * 2013-07-29 2013-10-24 Ssp Co Ltd 経口投与用製剤
JP6304896B2 (ja) * 2013-07-30 2018-04-04 ライオン株式会社 錠剤
SG11201600815WA (en) 2013-08-07 2016-03-30 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
HUE065006T2 (hu) 2014-07-03 2024-04-28 SpecGx LLC Nem-cellulóz poliszacharidokat tartalmazó, visszaélés-gátló, azonnali felszabadulású készítmények
CN108348775B (zh) 2015-09-15 2021-07-02 普瑞西斯生物学研究有限责任公司 芬坎法明的前药
UA126916C2 (uk) 2017-04-27 2023-02-22 Др. Редді'З Лабораторіз Лімітед Фармацевтична композиція кеторолаку
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
JP7393348B2 (ja) 2018-01-30 2023-12-06 インサイト・コーポレイション （１－（３－フルオロ－２（トリフルオロメチル）イソニコチニル）ピぺリジン―４－オン）を作製するためのプロセス及び中間体
CN113768934A (zh) 2018-03-30 2021-12-10 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
JP7170437B2 (ja) * 2018-06-29 2022-11-14 小林製薬株式会社 内服用医薬組成物
WO2020068510A1 (en) 2018-09-25 2020-04-02 SpecGx LLC Abuse deterrent immediate release capsule dosage forms
US11779541B2 (en) * 2019-03-26 2023-10-10 Johnson & Johnson Consumer Inc. Immediate release dosage form
BR112022009710A2 (pt) 2019-11-22 2022-08-09 Incyte Corp Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
JP7499025B2 (ja) * 2019-12-27 2024-06-13 小林製薬株式会社 内服用医薬組成物
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CA3124579C (en) 2020-07-15 2026-03-31 Schabar Research Associates Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
JP2023534810A (ja) 2020-07-15 2023-08-14 シャバー リサーチ アソシエイツ エルエルシー 急性痛の処置並びに胸やけの重症度及び／又はリスクの低減のための、イブプロフェン及びファモチジンから構成される単位経口用量組成物
US12514846B2 (en) 2020-07-15 2026-01-06 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965072A (en) * 1988-11-03 1990-10-23 Miles Inc. Granulating composition and method
US5219574A (en) * 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
JP2906528B2 (ja) * 1990-02-14 1999-06-21 大正製薬株式会社 吸収を促進した内服用固形製剤
CA2061520C (en) * 1991-03-27 2003-04-22 Lawrence J. Daher Delivery system for enhanced onset and increased potency
EP0553777B1 (en) * 1992-01-29 2002-04-24 Takeda Chemical Industries, Ltd. Fast dissolving tablet and its production
JPH10500982A (ja) * 1994-05-27 1998-01-27 ファーマーク、ネダーランド、ベスローテン、フェンノートシャップ 医薬組成物
ZA959469B (en) 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition

Also Published As

Publication number Publication date
JP5026635B2 (ja) 2012-09-12
JP5622703B2 (ja) 2014-11-12
TR200100708T2 (tr) 2001-07-23
JP2002524492A (ja) 2002-08-06
JP2012082197A (ja) 2012-04-26
DE69905380T2 (de) 2003-11-27
EP1109534B1 (en) 2003-02-12
US6713089B1 (en) 2004-03-30
ATE232382T1 (de) 2003-02-15
EP1109534A1 (en) 2001-06-27
DK1109534T3 (da) 2003-06-10
AU5504599A (en) 2000-04-03
PT1109534E (pt) 2003-06-30
CA2343148A1 (en) 2000-03-23
CA2343148C (en) 2005-11-15
EA200100331A1 (ru) 2001-08-27
DE69905380D1 (de) 2003-03-20
WO2000015195A1 (en) 2000-03-23
EA004032B1 (ru) 2003-12-25

Similar Documents

Publication Publication Date Title
PT1109534E (pt) Composicoes farmaceuticas de farmacos de libertacao rapida
ES2543427T3 (es) Forma farmacéutica oral de deferasirox
DE60202794T2 (de) Orodispersible tablette mit hoher homogenität und herstellungsverfahren dafür
DE69934135D1 (de) Dosierungsformen enthaltend geschmacksmaskierten wirkstoffen
SK284645B6 (sk) Mnohočasticová tableta na báze častíc s potiahnutým aktívnym základom a zmesi nosičov
EA200601588A1 (ru) Стабилизированные перенасыщенные твёрдые растворы липофильных лекарственных средств
US5702721A (en) Transdermal therapeutic system exhibiting an increased active substance flow and process for the production thereof
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
HUP9801615A2 (hu) Szimetikon/vízmentes kalcium-foszfát-kompozíciók
CA2339991A1 (en) Microemulsions as solid dosage forms for oral administration
JPS61251617A (ja) １つ又はそれ以上の活性成分を液に調整放出する組成物及びその調整方法
ATE367802T1 (de) Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
RS62505B1 (sr) Sublingvalne tablete otporne na zloupotrebu koje sadrže buprenorfin i nalokson
Zimm et al. Drug release from a multiparticulate pellet system
EE200000186A (et) Osake, selliste osakeste valmistamismeetod ja kasutamine, farmatseutiline doosivorm ja selle valmistamismeetod, tahke dispersioon ja farmatseutiline pakend
EE200100104A (et) 5-HT4 agonisti või antagonisti uus peroraalne ravimvorm
Kuno et al. Effect of preparation method on properties of orally disintegrating tablets made by phase transition
JP2000119175A (ja) 口腔内速崩壊性固形製剤
Jacob et al. Preparation and evaluation of microencapsulated fast melt tablets of ambroxol hydrochloride
JP6308938B2 (ja) 粒状物を製造する方法
Usmani et al. Development and evaluation of orally disintegrating tablets of montelukast sodium by direct compression method
Guo et al. Investigation of the release of aspirin from spray-congealed micro-pellets
ITMI20010907A1 (it) Impiego di antagonisti oppioidi per la prevenzione ed il controllo degli effetti collaterali prodotti dagli oppioidi
JP3796848B2 (ja) 生薬類配合固形組成物